Dr. Siefker-Radtke discusses new mUC study results - Norse and THOR

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Dr. Arlene O. Siefker-Radtke (US) from the Depart. of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. She answers questions about the recent ASCO23 presentations on metastatic urothelial cancer (mUC), where new results of the phase II Norse study, and the phase III THOR study were shared.Phase II Norse study:Dr. Siefker-Radtke elaborates on the study rational and pleasing results of the phase II Norse study: Erdafitinib (erda) vs erda plus cetrelimab (erda+CET) for patients with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa). Single agent erdafitinib had an objective response rate of around 45%. The combination of erdafitinib and cetrelimab had an objective response rate of around 55%.  Single agent erdafitinib had a progression-free survival (PFS) of around 5.5 months, and the combination arm had a median survival of around 11 months. The median overall survival with erdafitinib alone was around 16 months, whereas the combination had a median overall survival of around 20.8 months.Phase III THOR study: Dr. Siefker discusses the phase III results whereby erda significantly improved overall and PFS, as well as overall response rate, compared with chemotherapy, in patients with advanced or mUC and FGFR alteration who already had been treated with a PD-(L)1 inhibitor. For more details on these studies, you can read the abstracts on the UROONCO educational platform - phase II Norse, phase III THOR.